Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | POLB | P06746 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008899 | 0.91 | MEN1 (0.70) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL12008902 | 0.90 | MEN1 (0.76) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL12008889 | 0.88 | MEN1 (0.89) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL12008839 | 0.86 | MEN1 (1.00) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL12008943 | 0.86 | KMT2A (0.84) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL12008910 | 0.86 | KMT2A (0.82) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL12009000 | 0.85 | MEN1 (0.72) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL12008909 | 0.85 | MEN1 (0.72) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL12008904 | 0.85 | MEN1 (0.71) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL12008903 | 0.84 | MEN1 (0.68) | MEN1KMT2AMAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | MEN1 4655/4885KMT2A 4591/4885MAPT 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.